Abstract A29: An Ad5 [E1-, E2b-] platform carrying the TAA CEA(6D) induces CEA directed CMI responses in patients with advanced CEA-expressing colorectal cancer in a phase I/II clinical trial..

Published

Journal Article

Full Text

Duke Authors

Cited Authors

  • Morse, MA; Gabitzsch, ES; Xu, Y; Rajesh, D; Nguyen, S; Balcaitis, S; Balint, JP; Jones, F

Published Date

  • January 1, 2013

Published In

  • Combinatorial Immune Based Therapies

Published By

Digital Object Identifier (DOI)

  • 10.1158/1538-7445.tumimm2012-a29